We are leaders in
CRISPR/Cas9 gene targeting. We have completed over 40 CRISPR/Cas9 projects including knockouts, reporter and point mutant knockins and targeted transgenics.
more details.
Our
fees are low, our
wait times are short and our
success rates are high. New transgenic and targeted mice that we have created are featured in over 200
publications since 2004.
We are supported by the
Case Western Reserve University School of Medicine the
Case Comprehensive Cancer Center and the
Clinical and Translational Science Collaborative.